You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
SBC: Noom, Inc. Topic: NIMHDESCRIPTION (provided by applicant): Bulimia nervosa and binge eating disorder are marked by significant levels of impairment and psychiatric comorbidity, affecting approximately 5-7% of the US population. Guided self-help cognitive behavioral (CBT-GSH) therapy has been show to be an effective treatment to reduce binge eating for patient with both disorders. However, there is limited uptake among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Increasing Access and Developing Predictors for Colorectal Cancer Screening for Minority and Medicaid Clients
SBC: Witness CARES, LLC Topic: 102ABSTRACT African Americans have 22% higher incidence and 49% higher death rates from CRC than any other ethnic/racial group. Similarly, lower socioeconomic status (SES) is also associated with higher CRC incidence and mortality. Both of these groups are overrepresented in Medicaid populations. Screening colonoscopy is a cost-effective cancer prevention and control strategy, leading to CRC preventi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Improving liver lesion biopsy in the CT suite through fusion with PET images
SBC: KITWARE INC Topic: NCIDESCRIPTION (provided by applicant): The broad objective of this proposal is to improve the clinical effectiveness of liver lesion biopsy by fusing respiratory-compensated PET with CT images in the CT suite. On CT imaging alone, localization of liver lesions can potentially be challenging, particularly in selected cases where differentiation of the tumor from adjacent liver parenchyma may be diffi ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Image-Based Quantification and Analysis of Longitudinal Lung Nodule Deformations
SBC: KITWARE INC Topic: NIBIBDESCRIPTION (provided by applicant): Image-based evaluation of pathologies over time is complicated by variability in image acquisition and patient positioning, deformations due to respiratory and cardiac motion, and the clinical standard in radiology of comparing unaligned images. This application proposes a computational method for longitudinal image analysis that captures, illustrates and quant ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Identification and Characterization of Causative Genetic Biomarkers for Parkinson
SBC: POPULATION DIAGNOSTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): The goal of this project is to rapidly discover biomarkers for Parkinson's Disease (PD) by defining the spectrum of causal genetic loci for PD, not only for the purpose of accurate diagnosis and risk stratification but also in order to shed light on the underlying biology and pathways involved in PD pathogenesis for the purpose of future rational therapeutic de ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Hybernia Safety Catheter for Neuroprotection via Selective Hypothermia
SBC: Hybernia Medical, LLC Topic: NINDSDESCRIPTION (provided by applicant): Hypothermia is a powerful neuroprotective treatment for ischemic injury and is indicated for use in cardiopulmonary bypass, cardiac arrest, and neonatal hypoxia. However, current methods induce systemic hypothermia which requires significant time and has associated complications. Hybernia Medical, LLC is developing a device based on intellectual property assign ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy to Protect the Lung from Oxidant Stress
SBC: LEXEO Therapeutics LLC Topic: NHLBIAbstractThe focus of this proposal is the development of therapy to protect the lung with an extracellular anti oxidant defense to treat chronic obstructive pulmonary diseaseCOPDa chronic disorder in which inhaled oxidants from tobacco smokepollution and generated within the lung by activated inflammatory cells perpetuate injury to the lung epithelium and endotheliumThe LEXEO strategy is to use in ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Gene Therapy to Prevent Esophageal Cancer Associated with Aldehyde Dehydrogenase Deficiency
SBC: LEXEO Therapeutics LLC Topic: 400AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using in vivo gene therapy technologies to treat disorders of unmet medical needLEXEO is developing an in vivo gene therapy strategy as a preventative therapy to protect individuals with aldehyde dehydrogenaseALDHdeficiency from the high risk for esophageal cancerAs the next step in the development paththe goal of this ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent
SBC: PHOTOLITEC LLC Topic: NCIDESCRIPTION (provided by applicant): Photolitec's patented technology is focused on developing improved agents for tumor- imaging, image-guided surgery and/or photodynamic therapy (PDT). The proposed STTR proposal includes fluorescence-image guided PDT, aSee and Treat approach. The fluorescence imaging compound with long wavelength absorption near 800 nm should be extremely useful for image ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk
SBC: ZENAGENE, INC. Topic: NCIDESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health